Uric acid and cardiometabolic diseases

Overview of attention for article published in Clinical Hypertension, June 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news: 39 news outlets

Citations

dimensions_citation: 45 Dimensions

Readers on

mendeley: 77 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 40 news stories from 39 outlets.

Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout

Biz Wire Express, 01 Dec 2021

GlobeNewswire 2021-12-01 -DISSOLVE program on track with 12-month study fully enrolled- -DISSOLVE II on track for full…

Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout

Ticker Tech, 01 Dec 2021

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc.

Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout

Yahoo! Finance USA, 01 Dec 2021

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc.

News story from PR Newswire UK on Wednesday 01 December 2021

PR Newswire UK, 01 Dec 2021

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 36 additional news stories.